Trial Profile
A single-center prospective observational cohort study of inflammatory bowel disease patients who switched from Remicade to CT-P13
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Jan 2020
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Crohn's disease; Inflammatory bowel diseases; Ulcerative colitis
- Focus Therapeutic Use
- 09 Oct 2017 New trial record